How common is low testosterone, and why are rates rising in younger men?
Listen to this article as a podcast episode
April 23, 2026 · 19:26
Symptomatic hypogonadism affects about 2% of men aged 40 to 79 under strict research criteria. The true burden is likely higher, because diagnosis requires persistent symptoms plus repeatedly low morning testosterone. Rates appear to be rising in younger men for two reasons at once: more men are being tested, and some drivers of testosterone decline, such as obesity, now begin earlier in life.
Find the cause before treating it
Choose a lab panel and get a clinical review with clear next steps.
Key takeaways
- In the European Male Ageing Study, about 2.1% of men aged 40 to 79 met strict criteria for symptomatic hypogonadism.[1] The Massachusetts Male Aging Study estimated about 12.3 new cases of androgen deficiency per 1,000 person-years.[2] Strict definitions and selective testing mean these figures likely undercount.
- Testosterone declines gradually with age. Weight gain and poor health are linked to lower levels on top of that decline, and weight loss is linked to a rise.[3] [4]
- In a Boston cohort, testosterone fell over calendar time in a way that aging, obesity, and smoking did not explain. That pattern is consistent with a generational decline.[5]
- Low testosterone is more common in men with obesity, type 2 diabetes, and chronic illness.[3] [6] Many hypogonadism statistics therefore reflect interconnected disease rather than isolated hormone failure.
- A low number alone is not a diagnosis. Male hypogonadism requires persistent symptoms plus consistently low testosterone.[7] [8] [9] LH and FSH are measured to classify primary versus secondary disease.
- Testosterone should be measured in the morning with an accurate assay, and a low result should be confirmed on a repeat test.[9]
How common is low testosterone really
In the European Male Ageing Study, about 2.1% of men aged 40 to 79 met strict criteria for symptomatic late-onset hypogonadism.[1] A 2004 Journal of Clinical Endocrinology and Metabolism analysis of the Massachusetts Male Aging Study estimated about 12.3 new cases of androgen deficiency per 1,000 person-years in middle-aged and older men.[2]
Prevalence means the proportion of men who meet diagnostic criteria at a given time. Incidence means the rate of new cases appearing over time.
A 2010 New England Journal of Medicine study from the European Male Ageing Study defined late-onset hypogonadism with three requirements:[1]
- at least three sexual symptoms: poor morning erections, low sexual desire, and erectile dysfunction
- total testosterone below 11 nmol/L (about 320 ng/dL)
- free testosterone below 220 pmol/L (64 pg/mL)
Studies that use broader symptom sets or different thresholds report higher numbers, which is why published prevalence spans a range. These figures are best read as minimum estimates rather than a final count.
Low testosterone prevalence is often misunderstood in two opposite directions. Some men assume the condition is extremely common because fatigue, weight gain, and lower libido are common. Others assume it is rare because relatively few men carry a formal diagnosis. Male hypogonadism is a syndrome, not a screening label. A man needs persistent symptoms and biochemical evidence of testosterone deficiency. A low number alone is not enough, and symptoms alone are not enough either.[7] [8]
That diagnostic strictness makes published rates conservative. Clinical diagnosis requires a low morning testosterone result, confirmed on repeat testing, in a man with consistent symptoms.[9] Most men in the community never go through that process. For a deeper explanation of why the syndrome is defined this way, see What is low testosterone? The clinical definition most men (and many doctors) get wrong.
Why published rates undercount
Published hypogonadism statistics likely sit below the real-world burden because testing is selective, criteria are strict, and many symptomatic men are never evaluated.
Several things keep men out of the count:
- Many men with declining testosterone do not present until symptoms become disruptive.
- Others are tested once, at the wrong time of day, or without LH and FSH.
- Some are told their testosterone is “normal” because it falls inside a broad adult reference range, even when symptoms persist and free testosterone may be low.
- Others are never tested, because sexual symptoms are stigmatized or because fatigue and weight gain are put down to stress, work, or aging.
Published figures therefore count the men identified under strict research conditions, not every man affected.
Which groups carry the highest burden
Low testosterone is more common in men with obesity, type 2 diabetes, and chronic illness.[3] [6]
Comorbidity means a disease that exists alongside another disease. In hypogonadism, a comorbidity often contributes to the hormonal problem, and low testosterone can in turn worsen the comorbidity.
Obesity, diabetes, and metabolic syndrome
Obesity, type 2 diabetes, and metabolic syndrome are the conditions most often linked to low testosterone in routine clinical practice. A 2004 Journal of Clinical Endocrinology and Metabolism study by Dhindsa and colleagues found that about one third of 103 men with type 2 diabetes had low free testosterone, with lower LH and FSH than men whose free testosterone was normal.[6] That pattern is secondary hypogonadism: the testes can still respond, but the brain is not sending an adequate signal. It is a major reason functional hypogonadism is described as the most common real-world form of the condition.
Functional hypogonadism means low testosterone caused by suppression of the hormone axis that can reverse, rather than by permanent structural damage to the testes or pituitary. Obesity, insulin resistance, and some medications can push testosterone lower without destroying the system itself. In the European Male Ageing Study, weight loss was followed by a rise in testosterone. The authors concluded that obesity-related changes in the axis are reversible after weight reduction.[4]
These conditions reinforce each other. Visceral fat promotes inflammation and aromatase activity, which raises estradiol and suppresses gonadotropin output. Lower testosterone then worsens body composition, physical function, and insulin sensitivity.
Other high risk populations
Low testosterone is also reported more often in men with cardiovascular disease, COPD, kidney disease, and cancer. The pattern reflects chronic illness, inflammation, medication burden, and reduced physiologic reserve. Illness can suppress the hypothalamic-pituitary-gonadal axis, and some treatments used in these groups, such as opioids and glucocorticoids, may add further suppression. This is one reason hypogonadism statistics vary so widely by setting. Community studies, diabetes clinics, obesity clinics, and cardiology populations do not share the same baseline risk.
Men in these groups have a higher pretest probability of true androgen deficiency when persistent symptoms are present.
Why aging explains less than many men think
Testosterone declines with age, but gradually. Weight gain and poor health are linked to lower levels on top of that decline.[3] [4] The larger drops that bring men into clinic often reflect the weight gain and illness that accumulate with age, not age as an isolated force.
Healthy aging versus unhealthy aging
The European Male Ageing Study followed 2,736 men aged 40 to 79 at eight European centers for about 4.4 years.[4]
According to EMAS, the average yearly change was small. Total testosterone fell by about 0.1 nmol/L a year and free testosterone by about 3.8 pmol/L, while SHBG rose. Weight loss was associated with a rise in testosterone and weight gain with a fall. Free testosterone changed significantly only in men who gained or lost at least 15% of their body weight. Changes in the number of chronic conditions or in physical activity were not linked to significant changes in the axis.[4]
This helps explain why some men notice major symptoms in midlife while others do not. Body weight appears to matter more than chronological age. Sleep loss, diabetes, and medication exposure may add to the effect.
What the Massachusetts Male Aging Study showed
A 2002 Journal of Clinical Endocrinology and Metabolism analysis of the Massachusetts Male Aging Study by Feldman and colleagues followed 1,156 men for 7 to 10 years.[3] Within individual men, total testosterone declined about 1.6% per year and bioavailable testosterone about 2% to 3% per year. Comparing men of different ages at a single time point gave a shallower decline of about 0.8% per year for total testosterone.[3]
The study defined apparent good health as no chronic illness, no prescription medication, no obesity, and no excessive drinking. Men in good health had levels of several androgens 10% to 15% higher. The authors suggested that new illness during follow-up may accelerate the age-related decline.[3]
Smoking complicates this research. In EMAS, men who quit smoking had a larger testosterone decline than men who had never smoked, independent of weight change.[4] That does not make smoking protective in any clinical sense. Falling smoking rates also do not explain the generational trend. The Boston analysis of population-level decline found the decline was not attributable to observed changes in smoking or obesity.[5]
What the generational decline data show
Cohort data suggest a generational testosterone decline. Men of a given age measured in later years appear to have lower testosterone than men of the same age measured earlier.[5]
Age matched means the comparison is made between men of the same age who were born in different years. That design separates “getting older” from “being born later.”
The U.S. birth cohort signal
A 2007 Journal of Clinical Endocrinology and Metabolism analysis by Travison and colleagues followed randomly selected men aged 45 to 79 in the Boston area across three waves between 1987 and 2004.[5] It found a substantial age-independent decline in serum testosterone. Changes in obesity, smoking, and other measured health factors did not explain the decline, and the estimated population-level drop was larger than the cross-sectional decline usually attributed to age. The authors proposed birth cohort differences, or health or environmental effects they had not measured, as possible causes.[5]
This is the core evidence behind the idea of generational testosterone decline. If the trend has continued, a man in his 40s today may have a lower testosterone distribution than a man of the same age a generation ago, even before obvious disease is diagnosed. The exact rate is uncertain, and the study did not include younger men. A downward shift in the population curve does not mean every later born man will have low testosterone. It does increase the number of men near symptomatic thresholds.
Parallel signals in male reproductive health
Broader male reproductive data also show change over time. Levine’s 2017 systematic review and meta-regression analysis in Human Reproduction Update pooled 185 studies of 42,935 men.[10] It looked at men unselected by fertility from North America, Europe, Australia, and New Zealand. Between 1973 and 2011, sperm concentration in this group fell 52.4% and total sperm count fell 59.3%.[10]
Sperm count is not the same thing as testosterone. These trends raise separate concerns about male reproductive health and are not direct evidence of a testosterone decline.
Why low testosterone in young men is rising
Low testosterone in young men is becoming more visible because testing has increased and because known risk factors such as obesity now appear earlier in life. Some of the apparent rise likely reflects better detection, and some appears to reflect a real biologic shift.
Earlier metabolic disease starts earlier hormone problems
Young men now reach adulthood with more metabolic risk than earlier generations. National survey data analyzed by Ogden and colleagues show that obesity among U.S. adolescents aged 12 to 19 roughly doubled between 1988 to 1994 and 2013 to 2014.[11] Many men may therefore enter their 20s already carrying excess weight. Weight gain is linked to lower testosterone, and weight loss to a rise.[4]
Chronic sleep deprivation, sedentary behavior, and ultra processed diets plausibly add to that early vulnerability by worsening body composition and metabolic health.
Environmental and medication exposures
Young men also accumulate environmental and medication exposures from childhood onward that may affect hormone signaling, fertility, or both.
Endocrine disrupting chemicals such as BPA, phthalates, and PFAS are a common concern because exposure begins early and is widespread. Evidence for these chemicals comes mainly from population and mechanistic studies. It is difficult to prove that one exposure caused a specific man’s low testosterone.
Medication exposure also starts earlier and lasts longer for many men. Opioids, glucocorticoids, and prior anabolic steroid or testosterone use can suppress the hormone axis. SSRIs and finasteride can cause sexual side effects that overlap with symptoms of low testosterone.
More testing has also changed the picture
Greater awareness likely means younger men are tested more often than they were a decade ago, so part of the apparent increase reflects detection rather than true prevalence. Direct to consumer hormone marketing, online symptom checkers, and broader discussion of men’s health have lowered the threshold for evaluation.
Detection alone is not a complete explanation. The age-independent decline reported by Travison suggests that at least part of the shift in testosterone is biological, although that study included only men aged 45 and older.[5]
| Driver | Why it matters | How strong the signal looks |
|---|---|---|
| Earlier obesity and insulin resistance | Suppresses the hormone axis and lowers free testosterone earlier in life | Strong clinical and epidemiologic support |
| Sleep loss, inactivity, and ultra processed diet | Worsen body composition and metabolic health | Consistent observational support |
| Medication exposure | Opioids, glucocorticoids, and anabolic steroids suppress the axis; SSRIs and finasteride can cause overlapping sexual symptoms | Strong for some drug classes, especially opioids and exogenous androgens |
| Environmental chemical exposure | May affect reproductive development and adult hormone signaling | Plausible, but hard to quantify at the individual level |
| More testing and awareness | Finds cases that previously went undiagnosed | Likely contributes to the apparent rise |
Why the true prevalence is probably higher than reported
The true prevalence of male hypogonadism is probably higher than published estimates. Routine screening is uncommon, diagnostic workups are often incomplete, and some causes stay hidden for years.
Underdiagnosis starts with missed patterns
Klinefelter syndrome illustrates the problem. A 2004 Lancet review by Lanfranco and colleagues described it as the most common genetic cause of male infertility.[12] The review noted that many cases remain undiagnosed because presentation varies and professional awareness is limited.[12] If a common genetic condition often goes unrecognized, broader undercounting across hypogonadism is plausible.
Many primary care settings still do not recognize the pattern that should trigger evaluation. Libido change, erectile dysfunction, reduced morning erections, increasing waist circumference, lower exercise tolerance, and persistent fatigue are often addressed separately instead of as one endocrine picture. Insurance barriers and stigma around sexual symptoms further reduce detection.
Incomplete testing is another reason prevalence is underestimated. The Endocrine Society’s 2018 guideline sets out the diagnostic steps:[9]
- measure testosterone in the morning with an accurate assay
- confirm a low result on a repeat test
- evaluate men with confirmed deficiency further to find the cause
That further evaluation includes LH and FSH. Without them, clinicians cannot tell primary from secondary hypogonadism or choose the correct treatment path. For the next step after prevalence data, see The complete low testosterone testing guide: what to order, when to test, and how to read results and Functional vs organic hypogonadism: is your low T reversible?.
COVID-19 and the population data gap
Research during the COVID-19 pandemic showed how closely testosterone tracks with acute illness. A 2024 review in Clinical Endocrinology by Groti Antonic and colleagues found that testosterone during acute COVID-19 was consistently lower in men with more inflammation and more severe illness.[13] The authors judged this most likely to be an effect of the illness on the hypothalamic-pituitary-testicular axis. The review also found that hypogonadism diagnosed before the pandemic was a risk factor for hospitalization. Whether COVID-19 increases the long-term incidence of hypogonadism remains unclear.[13]
Because acute illness itself lowers testosterone, a value measured during infection can be both a risk marker and a consequence of severe disease. Retesting after recovery is more informative.
The geographic picture is also incomplete. Some Nordic countries run national reproductive health monitoring, while the United States has no equivalent national testosterone surveillance program. Most major cohort studies also skew toward White Western populations. Reported racial and ethnic differences in testosterone are complicated by differences in SHBG, body composition, and access to care. Current hypogonadism statistics are informative but not fully representative.
Myth vs fact
Myth: Aging alone causes most low testosterone.
Fact: Testosterone declines gradually with age. Weight gain and poor health are linked to lower levels beyond that decline, and weight loss is linked to a rise.[3] [4]
Myth: Low testosterone in young men is mostly internet hype.
Fact: More testing has increased detection. Cohort data also show an age-independent population-level decline in testosterone, and sperm counts have fallen over several decades.[5] [10]
Myth: A single low testosterone number proves the diagnosis.
Fact: Male hypogonadism is a clinical syndrome. It requires persistent symptoms plus low morning testosterone on more than one occasion.[8] [9] LH and FSH are then checked to classify the cause.
Myth: Obesity, diabetes, and low testosterone are separate problems.
Fact: These conditions commonly reinforce one another. In one study, about one third of men with type 2 diabetes had low free testosterone.[6] Weight gain is associated with lower testosterone, and weight loss with a rise.[4]
Myth: The rise is only because men get tested more often.
Fact: Increased testing matters, but it does not explain an age-independent decline in measured testosterone within a single cohort. Sperm count trends also point to broader change in male reproductive health.[5] [10]
Bottom line
Under strict research criteria, about 2% of men aged 40 to 79 have symptomatic hypogonadism.[1] The true burden is probably higher because many men are never fully evaluated. The condition is becoming more relevant to younger men because obesity and other drivers now start earlier in life. The evidence suggests that both more testing and a real population-level decline in testosterone contribute.[5] For the full diagnostic and treatment roadmap, see the Low Testosterone hub.
Veedma offers testing across the U.S. that includes total and free testosterone measured by LC-MS/MS with LH and FSH, or a review of lab results a man already has. Licensed providers interpret the results and, when appropriate, prescribe enclomiphene or a tablet combining enclomiphene and tadalafil. Enclomiphene is not an FDA-approved drug; it is prescribed after a provider confirms the diagnosis and is compounded by a licensed U.S. pharmacy.
References
- Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123-35. PMID: 20554979
- Araujo AB, O’Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89:5920-6. PMID: 15579737
- Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87:589-98. PMID: 11836290
- Camacho EM, Huhtaniemi IT, O’Neill TW, et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol. 2013;168:445-55. PMID: 23425925
- Travison TG, Araujo AB, O’Donnell AB, et al. A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metab. 2007;92:196-202. PMID: 17062768
- Dhindsa S, Prabhakar S, Sethi M, et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:5462-8. PMID: 15531498
- Salonia A, Capogrosso P, Boeri L, et al. European Association of Urology Guidelines on Male Sexual and Reproductive Health: 2025 Update on Male Hypogonadism, Erectile Dysfunction, Premature Ejaculation, and Peyronie’s Disease. Eur Urol. 2025;88:76-102. PMID: 40340108
- Basaria S. Male hypogonadism. Lancet. 2014;383:1250-63. PMID: 24119423
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103:1715-1744. PMID: 29562364
- Levine H, Jørgensen N, Martino-Andrade A, et al. Temporal trends in sperm count: a systematic review and meta-regression analysis. Hum Reprod Update. 2017;23:646-659. PMID: 28981654
- Ogden CL, Carroll MD, Lawman HG, et al. Trends in Obesity Prevalence Among Children and Adolescents in the United States, 1988-1994 Through 2013-2014. JAMA. 2016;315:2292-9. PMID: 27272581
- Lanfranco F, Kamischke A, Zitzmann M, et al. Klinefelter’s syndrome. Lancet. 2004;364:273-83. PMID: 15262106
- Groti Antonic K, Antonic B, Caliber M, et al. Men, testosterone and Covid-19. Clin Endocrinol (Oxf). 2024;100:56-65. PMID: 37501254
Low energy, low libido, or brain fog?
Order your lab panelStart with a lab panel
Get a clinical review of your results and health history, with an explanation of the decision and next steps in your patient chat. If you are eligible and want treatment, choose a plan and save a card to book a video visit at no extra visit fee. Treatment billing starts only if prescribed.
Order your lab panelPrefer short video breakdowns? Follow @veedma.men on TikTok for quick, study-backed men's hormone explainers.

Vladimir Kotlov, MD: Founder & CEO at Veedma
Vladimir Kotlov, MD is the founder of Veedma. A urologist by training, he led a urology department at a fertility and reproductive clinic where he managed a team of 30+ clinicians and improved IVF outcomes by 24%. He then moved to Silicon Valley and spent five years advising healthtech companies before founding Veedma to help men access evidence-based hormone optimization and fertility care.